ASMB - NASDAQ
Assembly Biosciences, Inc.
$24.57
+0.33%Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAssembly Biosciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Assembly Biosciences, Inc. Income Statement
ASMB • NASDAQ
| Assembly Biosciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
72.3M | 28.5M | 7.2M | 0.0 | 6.3M | 79.1M | 16M | 14.8M | 9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||
(129K) | (0.0) | (48.9M) | (69.1M) | (0.0) | (101.3M) | (85.3K) | (72.7M) | (44.2M) | (80.3K) | (65K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
72.2M | 28.5M | -41.7M | -69.1M | 6.3M | -22.2M | 15.9M | -57.9M | -35.2M | -80.3K | -65K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||||||||||
(84.4M) | (73.9M) | (22.9M) | (25M) | (138.9M) | (42.5M) | (118.7M) | (107.5M) | (61.2M) | (45.3M) | (29.7M) | (24M) | (19.6M) | (24.9M) | (34M) | (4.8M) | (3.3M) | (7.2M) | |
(19.6M) | (18M) | (22.9M) | (23.9M) | (28.8M) | (36.9M) | (32.9M) | (34.8M) | (17M) | (12.2M) | (11.3M) | (13.2M) | (4.6M) | (5.3M) | (8.7M) | (2.9M) | (397.2K) | (1.2M) | |
(64.8M) | (55.9M) | (48.9M) | (70M) | (68.5M) | (106.8M) | (85.8M) | (72.7M) | (44.2M) | (33.1M) | (18.4M) | (10.7M) | (15M) | (19.5M) | (25.3M) | (1.9M) | (2.9M) | (6M) | |
-12.1M | -45.4M | -64.6M | -94.1M | -132.7M | -64.8M | -102.7M | -92.7M | -52.2M | -45.3M | -29.7M | -24M | -19.6M | -24.9M | -34M | -4.8M | -3.3M | -7.2M | |
PRE-TAX INCOME | ||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (116.7K) | (10.5M) | (1.2M) | (1.6M) | |
6M | 5.6M | 3.5M | 1M | 302K | 2.6M | 4.3M | 3.1M | 983K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -40.3K | -10.5M | -1.2M | -1.6M | |
(0.0) | (0.0) | -48.9M | -68.9M | (41.6M) | -101.1M | (5K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
6M | 5.6M | 3.5M | 1M | 302K | 2.6M | 4.3M | 3.1M | 368.2K | 398.8K | 1.2M | 167.7K | 201K | 65.1K | -342.7K | -15,290.6B | -1.2M | 0.0 | |
-6.1M | -39.8M | -61.2M | -93.1M | -132.4M | -62.2M | -98.4M | -89.7M | -51.9M | -44.9M | -28.5M | -23.8M | -19.4M | -24.8M | -34.3B | -15,290.6B | 0.0 | 0.0 | |
NET INCOME | ||||||||||||||||||
(0.0) | (330K) | (33K) | (0.0) | -2.5M | (0.0) | -774K | (1.1M) | -9.1M | -617.7K | (0.0) | (0.0) | (0.0) | (65.1K) | (342.7K) | -10,524.4B | (1.2M) | (1.6M) | |
-6.1M | -40.2M | -61.2M | -93.1M | -129.9M | -62.2M | -97.6M | -90.8M | -42.8M | -44.3M | -28.5M | -23.8M | -19.4M | -24.8M | -34.3M | -15.3M | -4.5M | -8.8M |
SEC Filings
ASMB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 22, 2026 | May 22, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 24, 2026 | 2026 | |
S-3 S-3 N/A | March 19, 2026 | March 19, 2026 | ||
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 |
Related Guides
Continue your ASMB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.